Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) – Equities researchers at HC Wainwright decreased their Q2 2024 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Thursday, April 25th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($0.28) per share for the quarter, down from their previous estimate of ($0.19). HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q3 2024 earnings at ($0.29) EPS, Q4 2024 earnings at ($0.30) EPS and FY2024 earnings at ($1.14) EPS.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same period in the prior year, the business earned ($0.25) EPS.
Read Our Latest Report on VKTX
Viking Therapeutics Trading Up 5.5 %
Shares of Viking Therapeutics stock opened at $79.58 on Monday. The business has a fifty day simple moving average of $69.90 and a two-hundred day simple moving average of $36.01. The firm has a market capitalization of $8.78 billion, a P/E ratio of -85.57 and a beta of 1.05. Viking Therapeutics has a 12 month low of $8.28 and a 12 month high of $99.41.
Hedge Funds Weigh In On Viking Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of VKTX. Perpetual Ltd bought a new stake in shares of Viking Therapeutics in the first quarter worth $78,586,000. American Century Companies Inc. grew its stake in shares of Viking Therapeutics by 59.6% during the 3rd quarter. American Century Companies Inc. now owns 2,202,228 shares of the biotechnology company’s stock valued at $24,379,000 after purchasing an additional 822,156 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in shares of Viking Therapeutics during the 4th quarter valued at about $12,341,000. Goldman Sachs Group Inc. lifted its stake in shares of Viking Therapeutics by 88.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,119,885 shares of the biotechnology company’s stock worth $20,841,000 after purchasing an additional 525,296 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Viking Therapeutics by 194.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 765,320 shares of the biotechnology company’s stock worth $8,472,000 after purchasing an additional 505,578 shares during the period. 76.03% of the stock is owned by institutional investors.
Insider Transactions at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan sold 25,000 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $28.05, for a total transaction of $701,250.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Brian Lian sold 269,079 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $26.87, for a total value of $7,230,152.73. Following the sale, the chief executive officer now owns 2,184,882 shares in the company, valued at $58,707,779.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sarah Kathryn Rouan sold 25,000 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $28.05, for a total transaction of $701,250.00. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.
About Viking Therapeutics
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Hilton Demonstrates Asset Light is Right for Investors
- Find and Profitably Trade Stocks at 52-Week Lows
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.